Atara's pipeline includes tab-cel (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative
disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies.
Atara Biotherapeutics announced an updated development plan for the Phase 3 tab-cel program for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative
Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative
Disease Patients: Factors Influencing Engraftment.
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to United States-based Viracta Therapeutics, Incorporated's Phase two drug candidate, nanatinostat, in combination with the antiviral valganciclovir intended for the treatment of post-transplant lymphoproliferative
disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma, it was reported yesterday.
INDOLENT T-CELL LYMPHOPROLIFERATIVE
DISORDER OF THE GI TRACT
2), so the cytologic diagnosis was lymphoproliferative
Factors that appeared unlinked with PTAA included acute organ rejection, duration of post-transplantation steroidal treatment, organ type (living versus cadaveric), donor/recipient blood type and compatibility, infections besides Epstein-Barr virus, and posttransplant lymphoproliferative
disease (PTLD) is a significant complication of pediatric solid-organ transplantation, with a reported incidence of 6%-20% and a mortality rate of 12%-60% (1-3).
It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative
disorders, along with primary cutaneous anaplastic large cell lymphoma (primary C-ALCL) with which it shares overlapping clinical and histopathologic features.
Alpha HCD typically affects the gastrointestinal system, whereas y HCD has a heterogeneous clinical presentation, ranging from an asymptomatic state to aggressive lymphoproliferative
After 6 years, the cystic lung lesions gradually enlarged and increased in number (Figure 3), but she remained to have no respiratory symptoms, no decrease in FEV1 (1.18 L), and no findings of lymphoproliferative